Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2024-02-28 Regulatory Filings
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
POSASR
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form S-3 filed with the SEC by Mersana Therapeutics, Inc. It is a regulatory filing related to securities registration under the Securities Act of 1933. The document includes a prospectus for offering securities up to $300 million, describing the terms of the securities and the manner of offering. It references the SEC registration number and includes legal and procedural disclosures typical of a registration statement amendment. There is no substantive financial data or detailed financial report content such as an annual report or earnings release. The document is not a report itself but an amendment to a registration statement, which is a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-28 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2024, by Mersana Therapeutics, Inc. It announces the issuance of a press release with business updates and financial results for the fiscal quarter and year ended December 31, 2023. The document states that the press release is furnished as an exhibit and that the information is not "filed" for purposes of certain SEC rules. It also mentions posting an updated corporate presentation on the company's website. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information and provides references to where it can be found. According to the "Menu vs Meal" rule, this is an announcement of a report (press release and presentation) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-02-28 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-02-16 English
SC 13G/A
Major Shareholding Notification
2024-02-15 English
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP
Major Shareholding Notification
2024-02-15 English
AMENDMENT NO. 1
Major Shareholding Notification
2024-02-15 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.